Today’s Stock Alert: A Reversal for Medgenics Inc Is Not Near. The Stock Declines Again

Today's Stock Alert: A Reversal for Medgenics Inc Is Not Near. The Stock Declines Again

The stock of Medgenics Inc (NASDAQ:MDGN) is a huge mover today! The stock decreased 5.83% or $0.26 during the last trading session, hitting $4.2. About 184,154 shares traded hands or 22.66% up from the average. Medgenics Inc (NASDAQ:MDGN) has declined 3.25% since April 4, 2016 and is downtrending. It has underperformed by 4.34% the S&P500.
The move comes after 9 months negative chart setup for the $165.46M company. It was reported on Nov, 4 by We have $3.61 PT which if reached, will make NASDAQ:MDGN worth $23.16M less.

According to Zacks Investment Research, “Medgenics, Inc. is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company’s Biopump Platform Technology uses the patient’s own tissue for the treatment of a range of chronic diseases. Its products include EPODURE focused on the treatment of chronic renal anemia and INFRADURE focused on the treatment of hepatitis C. Medgenics, Inc. is based in Vienna, Virginia.”

Insitutional Activity: The institutional sentiment increased to 2.44 in Q2 2016. Its up 1.27, from 1.17 in 2016Q1. The ratio improved, as 2 funds sold all Medgenics Inc shares owned while 14 reduced positions. 14 funds bought stakes while 25 increased positions. They now own 15.20 million shares or 11.31% more from 13.66 million shares in 2016Q1.
American Grp owns 14,026 shares or 0% of their US portfolio. State Street holds 0% of its portfolio in Medgenics Inc (NASDAQ:MDGN) for 293,152 shares. Bancorp Of America De last reported 2,941 shares in the company. Sabby Management Limited holds 0.04% of its portfolio in Medgenics Inc (NASDAQ:MDGN) for 138,777 shares. Alyeska Inv Group Lp holds 0.01% or 100,000 shares in its portfolio. Moreover, Teachers has 0% invested in Medgenics Inc (NASDAQ:MDGN) for 34,272 shares. Belmont Advsr Inc has 0.11% invested in the company for 20,000 shares. Kistler owns 690 shares or 0% of their US portfolio. Blackrock Inc holds 1,528 shares or 0% of its portfolio. Blackrock Mgmt Ltd Liability Corp accumulated 89,373 shares or 0% of the stock. Adage Cap Prtn Group Ltd Liability Com, a Massachusetts-based fund reported 2.10 million shares. Blackrock Institutional Trust Na holds 624,997 shares or 0% of its portfolio. Price T Rowe Assoc Incorporated Md holds 0% of its portfolio in Medgenics Inc (NASDAQ:MDGN) for 761,200 shares. Jacobs Levy Equity holds 0% or 15,900 shares in its portfolio. White Pine Lc reported 20,000 shares or 0.05% of all its holdings.

More important recent Medgenics Inc (NASDAQ:MDGN) news were published by: which released: “Medgenics Presents New Data Showing Prevalence of Genetic Mutations in …” on October 29, 2016, also published article titled: “Why Medgenics Inc.’s Shares Are Down Big Today”, published: “Medgenics Inc. MDGN (US: Nasdaq)” on April 10, 2011. More interesting news about Medgenics Inc (NASDAQ:MDGN) was released by: and their article: “Medgenics Acquires Phase 2-Ready CNS Program: NFC-1” with publication date: September 09, 2015.

MDGN Company Profile

Medgenics, Inc., incorporated on January 27, 2000, is a clinical-stage biopharmaceutical company. The Firm focuses on genomic medicine. The Firm is engaged in the development of NFC-1. NFC-1 is a non-stimulant metabotropic glutamate receptor (mGluR) neuromodulator for the treatment of mGluR network mutation positive Attention Deficit Hyperactivity Disorder (ADHD), as well as neuropsychiatric symptoms resulting from a related genetic disorder, 22q11.2 Deletion Syndrome (22q11.2 DS). The Firm has completed a Phase Ib clinical of NFC-1 in adolescents with ADHD and disruptions in the mGluR gene network.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment